Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Landray

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Circulation|August 23, 2000
Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?J Thambyrajah, M J Landray, F J McGlynn, et al.
Journal of Human Hypertension|June 26, 2002
Oxidative stress in malignant and non-malignant phase hypertensionG Y H Lip, E Edmunds, S L Nuttall, et al.
QJM : Monthly Journal of the Association of Physicians|June 8, 2001
Dyslipidaemia in patients with malignant-phase hypertensionE Edmunds, M J Landray, F L Li-Saw-Hee, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 5, 2001
Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairmentM J Landray, J Thambyrajah, F J McGlynn, et al.
QJM : Monthly Journal of the Association of Physicians|February 28, 2002
Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertensionM J Landray, E Edmunds, F L Li-Saw-Hee, et al.
American Heart Journal|April 30, 2017
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics, L Bowman, F Chen, et al.
BMC Nephrology|May 3, 2017
Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal ProtectionC Reith, N Staplin, W G Herrington, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Circulation|August 23, 2000
Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?J Thambyrajah, M J Landray, F J McGlynn, et al.
Journal of Human Hypertension|June 26, 2002
Oxidative stress in malignant and non-malignant phase hypertensionG Y H Lip, E Edmunds, S L Nuttall, et al.
QJM : Monthly Journal of the Association of Physicians|June 8, 2001
Dyslipidaemia in patients with malignant-phase hypertensionE Edmunds, M J Landray, F L Li-Saw-Hee, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 5, 2001
Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairmentM J Landray, J Thambyrajah, F J McGlynn, et al.
QJM : Monthly Journal of the Association of Physicians|February 28, 2002
Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertensionM J Landray, E Edmunds, F L Li-Saw-Hee, et al.
American Heart Journal|April 30, 2017
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics, L Bowman, F Chen, et al.
BMC Nephrology|May 3, 2017
Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal ProtectionC Reith, N Staplin, W G Herrington, et al.
Pageof 3